<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329757</url>
  </required_header>
  <id_info>
    <org_study_id>FHNP-CT001</org_study_id>
    <nct_id>NCT01329757</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Growth Hormone Treatment in Spinal Cord Injury</brief_title>
  <acronym>GHSCI</acronym>
  <official_title>Efficacy and Safety of Growth Hormone (GH) Treatment in Spinal Cord Injury(SCI): A Triple-blinded, Randomised, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Nacional de Parapléjicos de Toledo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Salud y Politicas Sociales (Ministry of Health)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Nacional de Parapléjicos de Toledo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To evaluate the efficacy and safety of one year treatment based on daily doses of
      exogenous growth hormone (GH) in patients with traumatic spinal cord injury. The first six
      months the pharmacological treatment will be associated to rehabilitation treatment.

      The main hypothesis is that GH can improve motor function of patients with traumatic spinal
      cord injury below the lesion level. The hypothesis is based on possible effects of GH at
      muscle and synaptic level. GH can also promote axonal growth and regeneration.

      Design: Clinical trial placebo-controlled, double-blind intervention with blind evaluation by
      third parties and blinding in the analysis of data (triple-blind design).

      Duration of intervention and monitoring: 364 days.

      Primary outcome measures. Changes of the American Spinal Injury Association (ASIA) scale
      (motor score)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Score of the American Spinal Injury Association (ASIA) scale</measure>
    <time_frame>12 months</time_frame>
    <description>Motor score of the ASIA scale reports the strenght of 10 key muscles in each body side (5 key muscles in upper limb and 5 key muscles in lower limb). The strenght is rated between 0 and 5 (Medical Research Council-MRC scale). The ASIA motor score range is between 0 and 100 (normal).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASIA</measure>
    <time_frame>12 months</time_frame>
    <description>ASIA grades</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASIA sensory score</measure>
    <time_frame>12 months</time_frame>
    <description>ASIA sensory score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity</measure>
    <time_frame>Baseline, 15 days, 6 months, 12 months</time_frame>
    <description>Penn scale and Ashworth scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Baseline, 15 days, 6 months, 12 months</time_frame>
    <description>Visual analogic scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independence Measures and Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Spinal Cord Indipendence Measures (SCIM) and the Quality of Life Questionnaire (EQ 5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological Measures</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Motor Evoked Potentials, Somatosensory Evoked Potentials, Motor Neurography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>15, 30, 60, 90, 120, 150, 180, 360 days</time_frame>
    <description>Recording of any adverse event, full blood and urine examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>GH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of a daily dose of GH (0.4mg)for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of a daily dose of placebo for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GH</intervention_name>
    <description>Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year</description>
    <arm_group_label>GH</arm_group_label>
    <other_name>Genotonorm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of a subcutaneously injected daily dose of placebo for 1 year</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Provided by the Genotonorm producer (Pfizer)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Traumatic Spinal cord injury

          -  Incomplete (ASIA scale B or C)

          -  Level of injury: Between C4 and D12

          -  More than 18 months from the SCI injury.

        Exclusion Criteria:

          -  Non traumatic Spinal cord injury

          -  Complete SCI (ASIA A)

          -  Incomplete (ASIA D or E)

          -  Less than 18 months from the SCI

          -  Intensive Care Unit (ICU) staying for a period of 2 months or more

          -  More than 3 urological infections in the last year

          -  Pneumonia in the 6 months prior to the study

          -  Severe respiratory failure

          -  History of head trauma

          -  Severe psychiatric disorder

          -  A history of heart disease, diabetes or hypertension

          -  Concomitant Neurological Diseases

          -  Regular use of substances of abuse

          -  Patients with severe kidney and / or liver failure.

          -  Patients who can not be included in an intensive rehabilitation program

          -  Patients who are pregnant or breast-feeding

          -  History of malignancy

          -  Impossibility to obtain informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Oliviero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nacional de Paraplejicos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Nacional de Paraplejicos</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>January 9, 2015</last_update_submitted>
  <last_update_submitted_qc>January 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Nacional de Parapléjicos de Toledo</investigator_affiliation>
    <investigator_full_name>Antonio Oliviero</investigator_full_name>
    <investigator_title>MD, PhD, Neurologist</investigator_title>
  </responsible_party>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>Growth Hormone</keyword>
  <keyword>Trauma</keyword>
  <keyword>Incomplete</keyword>
  <keyword>ASIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

